Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Hong Kong
  4. Hong Kong Stock Exchange
  5. CanSino Biologics Inc.
  6. News
  7. Summary
    6185   CNE100003F01

CANSINO BIOLOGICS INC.

(6185)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

CanSino Biologics : COVID shot drives CanSinoBIO's first six-month profit since at least 2019

08/27/2021 | 10:10am EDT
FILE PHOTO: China's vaccine specialist CanSino Biologics Inc in Tianjin

BEIJING (Reuters) - Chinese vaccine maker CanSino Biologics Inc (CanSinoBIO) said on Friday it had returned to operating profit of 802.3 million yuan ($123.79 million) in the first six months of 2021, driven by use of its COVID-19 shot. That compared with 123.0 million yuan of operating loss in the same period a year ago, CanSinoBIO said in a filing in the Hong Kong stock exchange. It marks the first six-month profit since at least 2019. The firm is yet to achieve full-year profits since it went public in 2018 in Hong Kong.

It reported 937.1 million yuan profit and total comprehensive income for the first six months of 2021. Its single-dose COVID-19 shot, named Ad5-nCoV, has been approved for use in countries including China, Mexico, Pakistan and Chile. The vaccine approvals were one of the major drivers for the sixth-month profit, CanSinoBIO said.

($1 = 6.4813 Chinese yuan renminbi)

(Reporting by Roxanne Liu and Ryan Woo; Editing by Catherine Evans)


© Reuters 2021
All news about CANSINO BIOLOGICS INC.
10/20CANSINO BIOLOGICS : Restricting travel over vaccine type could be discrimination, PAHO war..
RE
10/11CanSino Biologics Inc. Announces Appointment of Jing Wang as an Executive Director
CI
10/09CANSINO BIOLOGICS : GLOBALink | Argentina uses Chinese CanSino COVID-19 vaccine to immuniz..
PU
10/05OCUGEN : Bharat Biotech Enter Supply Deal for COVID-19 Vaccine Candidate; Commercializatio..
MT
09/24CANSINO BIOLOGICS : CanSinoBIO's COVID vaccine, tested at lower dosage, safe for children ..
RE
09/20CANSINO BIOLOGICS INC.(XSSC : 688185) added to S&P Global BMI Index
CI
09/10Cansino Biologics Inc. Announces Executive Changes
CI
09/07CANSINO BIOLOGICS : Indonesia approves J&J, Cansino COVID-19 vaccines for emergency use
RE
09/07SINOVAC BIOTECH : Mixing CanSinoBIO, Sinovac COVID shots induces stronger response than Si..
RE
09/06CORONAVIRUS PANDEMIC : Chinese developer shares efficacy of inhaled vaccines
PU
More news
Analyst Recommendations on CANSINO BIOLOGICS INC.
More recommendations
Financials
Sales 2021 9 984 M 1 564 M 1 564 M
Net income 2021 2 378 M 372 M 372 M
Net cash 2021 5 073 M 795 M 795 M
P/E ratio 2021 8,98x
Yield 2021 0,00%
Capitalization 58 882 M 9 223 M 9 224 M
EV / Sales 2021 5,39x
EV / Sales 2022 1,77x
Nbr of Employees 726
Free-Float 37,1%
Chart CANSINO BIOLOGICS INC.
Duration : Period :
CanSino Biologics Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CANSINO BIOLOGICS INC.
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 8
Last Close Price 180,69 CNY
Average target price 308,63 CNY
Spread / Average Target 70,8%
EPS Revisions
Managers and Directors
Xue Feng Yu Chairman, Chief Executive Officer & GM
Xi Luo Chief Financial Officer
Jiang Feng Li Chairman-Supervisory Board
Tao Zhu Executive Director, CSO & Deputy General Manager
Jun Qiang Li Senior Director-Research & Development
Sector and Competitors
1st jan.Capi. (M$)
CANSINO BIOLOGICS INC.24.65%9 220
CSL LIMITED4.48%100 550
WUXI BIOLOGICS (CAYMAN) INC.10.21%61 723
SAMSUNG BIOLOGICS CO.,LTD.6.54%48 773
ALEXION PHARMACEUTICALS, INC.0.00%40 336
BIOGEN INC.10.35%40 270